KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business OfficerRead More
With its proprietary CHO-M cell line and SUREtechnology™ protein expression platform, Selexis provides partners worldwide with stable cell lines producing virtually any recombinant therapeutic protein at a high level and with consistent quality attributes. Over the last twenty years, Selexis has expressed both classical and novel scaffolds with increased levels of secretion complexity, such as:
Here is an overview of some expressed protein formats at Selexis. Selexis has also expressed many others that remain undisclosed.
Among the 10 marketed products and 160+ clinical phase products developed with Selexis’ proprietary technology, there are many different Fc fusion proteins:
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.